Armed T cells with CAR for cancer immunotherapy  

作　　者：Yu-Quan Wei 

机构地区：[1]State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

出　　处：《Science China(Life Sciences)》2016年第4期331-332,共2页中国科学（生命科学英文版）

摘　　要：The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor(CAR)to a desired antigen began in the 1990s(Gross et al.,1989;Kuwana et al.,1987).In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted(Lamers et al.,2006).Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia(Porter et al.,2011).Subsequently。The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor（CAR）to a desired antigen began in the 1990s（Gross et al.,1989;Kuwana et al.,1987）.In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted（Lamers et al.,2006）.Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia（Porter et al.,2011）.Subsequently,

关 键 词：immunotherapy refractory somatic lymphoid desired fight exert specificity enabled myeloma 

分 类 号：R730.51[医药卫生—肿瘤]